Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
3.
Nurs Womens Health ; 19(3): 236-46; quiz 247, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26058906

RESUMO

Intrauterine fetal demise (IUFD), or stillbirth, is the death of a fetus greater than 20 weeks gestation. Several factors contribute to risk for IUFD, although in many cases the exact etiology is unknown. Nurses are a vital part of the interdisciplinary health care team caring for families with IUFD, who require timely and sensitive care to enable an uncomplicated birth and grieving process.


Assuntos
Saúde da Família , Morte Fetal , Feminino , Idade Gestacional , Humanos , Gravidez , Estudos Retrospectivos , Fatores de Risco
4.
Expert Rev Pharmacoecon Outcomes Res ; 14(5): 589-98, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25138162

RESUMO

Crohn's disease (CD) is a chronic inflammatory condition that can affect any part of the gastrointestinal tract. It leads to severe symptoms and reduced quality of life. Infliximab is a monoclonal antibody against TNF-α and is effective in treating moderate to severe CD. It is associated with high treatment costs, but subsequent reductions in hospitalisation and surgery have been reported. This review examines the evidence for the cost-effectiveness of infliximab for the treatment of CD. Studies have been found to be very heterogeneous depending on setting, costs assumed and clinical data. Within the UK setting infliximab has been found to be cost effective with increased costs of around £25,000 per quality adjusted life year gained.


Assuntos
Anti-Inflamatórios/economia , Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais/economia , Anticorpos Monoclonais/uso terapêutico , Doença de Crohn/tratamento farmacológico , Doença de Crohn/economia , Custos de Medicamentos , Fármacos Gastrointestinais/economia , Fármacos Gastrointestinais/uso terapêutico , Redução de Custos , Análise Custo-Benefício , Doença de Crohn/diagnóstico , Custos Hospitalares , Humanos , Infliximab , Modelos Econômicos , Qualidade de Vida , Anos de Vida Ajustados por Qualidade de Vida , Índice de Gravidade de Doença , Medicina Estatal/economia , Fatores de Tempo , Resultado do Tratamento , Reino Unido
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...